Healthcare Industry News: Endocare
News Release - August 13, 2008
Endocare Rejects Unsolicited Proposal From HealthTronics
IRVINE, Calif., Aug. 13 (HSMN NewsFeed) -- Endocare, Inc. (Nasdaq: ENDO ) announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN ) to purchase all of the outstanding shares of Endocare for $2.28 per share. After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.About Endocare
Endocare, Inc. -- http://www.Endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).
Source: Endocare
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
